Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos O Ontiveros

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Cancer Immunology Research|September 28, 2023
Considerations and Approaches for Cancer Immunotherapy in the Aging HostCarlos O Ontiveros, Clare E Murray, Grace Crossland, et al.
Frontiers in Immunology|June 24, 2021
Reversing Post-Infectious Epigenetic-Mediated Immune SuppressionAbhimanyu, Carlos O Ontiveros, Rosa S Guerra-Resendez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2024
Cutting Edge: Cytosolic Receptor AIM2 Is Induced by Peroxisome Proliferator-activated Receptor γ following Mycobacterium tuberculosis Infection of Human Macrophages but Does Not Contribute to IL-1β ReleaseEusondia Arnett, Jade Wolff, Chrissy M Leopold Wager, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon productionClare E Murray, Carlos O Ontiveros, Jordan Wentworth, et al.
Plos Neglected Tropical Diseases|February 8, 2023
Genomic and phenotypic analyses suggest moderate fitness differences among Zika virus lineagesGlenn Oliveira, Chantal B F Vogels, Ashley Zolfaghari, et al.
Nature Communications|November 19, 2025
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signallingCarlos O Ontiveros, Myrna G Garcia, Clare E Murray, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Cancer Immunology Research|September 28, 2023
Considerations and Approaches for Cancer Immunotherapy in the Aging HostCarlos O Ontiveros, Clare E Murray, Grace Crossland, et al.
Frontiers in Immunology|June 24, 2021
Reversing Post-Infectious Epigenetic-Mediated Immune SuppressionAbhimanyu, Carlos O Ontiveros, Rosa S Guerra-Resendez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2024
Cutting Edge: Cytosolic Receptor AIM2 Is Induced by Peroxisome Proliferator-activated Receptor γ following Mycobacterium tuberculosis Infection of Human Macrophages but Does Not Contribute to IL-1β ReleaseEusondia Arnett, Jade Wolff, Chrissy M Leopold Wager, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon productionClare E Murray, Carlos O Ontiveros, Jordan Wentworth, et al.
Plos Neglected Tropical Diseases|February 8, 2023
Genomic and phenotypic analyses suggest moderate fitness differences among Zika virus lineagesGlenn Oliveira, Chantal B F Vogels, Ashley Zolfaghari, et al.
Nature Communications|November 19, 2025
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signallingCarlos O Ontiveros, Myrna G Garcia, Clare E Murray, et al.
Pageof 1